Recently, we demonstrated that R-Tf-D-LP4 may be a potential treatment for diabetes mellitus [27], and in addition to liver cancer, it also attenuates non-alcoholic steatohepatitis (NASH) and steatosis [28]. Here, DLGAP4 is linked to metabolic dysfunction-associated steatohepatitis.